Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective

Garry McDowell, M Slevin, J Krupinski

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Coronary in stent restenosis remains a significant limitation to the long term efficacy of coronary artery stent placement. In this review the authors review the pathophysiology of coronary in stent restenosis, together with an overview of the current treatment modalities. The potential clinical utility of nanotechnology is also reviewed. The first human safety trial of systemic nanoparticle paclitaxel (nab-paclitaxel) for in stent restenosis (SNAPIST-I) is discussed. The results showed no significant adverse advents attributable to the nab-paclitaxel at 10 or 30 mg/m, although moderate neutropenia, sensory neuropathy and mild to moderate reversible alopecia occurred at higher doses. No major adverse cardiac events were recorded at 2 months, whilst at 6 months, 4 target lesions required revascularisation. The investigators concluded therefore that systemic nab-paclitaxel was well tolerated at a dose of <70 mg/m. To date however, no formal clinical evaluation has been reported as to the clinical utility of nab-paclitaxel, or any of the nano preparations discussed, for the suppression of coronary in stent restenosis.
Original languageEnglish
JournalVascular Cell
Volume3:8
DOIs
Publication statusPublished - 2011

Fingerprint

Nanotechnology
Stents
Alopecia
Paclitaxel
Neutropenia
Nanoparticles
Coronary Vessels
Research Personnel
Safety
130-nm albumin-bound paclitaxel

Cite this

McDowell, Garry ; Slevin, M ; Krupinski, J. / Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective. In: Vascular Cell. 2011 ; Vol. 3:8.
@article{d582233e696d4f939507019bda1ee5b9,
title = "Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective",
abstract = "Coronary in stent restenosis remains a significant limitation to the long term efficacy of coronary artery stent placement. In this review the authors review the pathophysiology of coronary in stent restenosis, together with an overview of the current treatment modalities. The potential clinical utility of nanotechnology is also reviewed. The first human safety trial of systemic nanoparticle paclitaxel (nab-paclitaxel) for in stent restenosis (SNAPIST-I) is discussed. The results showed no significant adverse advents attributable to the nab-paclitaxel at 10 or 30 mg/m, although moderate neutropenia, sensory neuropathy and mild to moderate reversible alopecia occurred at higher doses. No major adverse cardiac events were recorded at 2 months, whilst at 6 months, 4 target lesions required revascularisation. The investigators concluded therefore that systemic nab-paclitaxel was well tolerated at a dose of <70 mg/m. To date however, no formal clinical evaluation has been reported as to the clinical utility of nab-paclitaxel, or any of the nano preparations discussed, for the suppression of coronary in stent restenosis.",
author = "Garry McDowell and M Slevin and J Krupinski",
year = "2011",
doi = "10.1186/2045-824X-3-8",
language = "English",
volume = "3:8",
journal = "Vascular Cell",
issn = "2045-824X",
publisher = "BioMed Central Ltd.",

}

Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective. / McDowell, Garry; Slevin, M; Krupinski, J.

In: Vascular Cell, Vol. 3:8, 2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective

AU - McDowell, Garry

AU - Slevin, M

AU - Krupinski, J

PY - 2011

Y1 - 2011

N2 - Coronary in stent restenosis remains a significant limitation to the long term efficacy of coronary artery stent placement. In this review the authors review the pathophysiology of coronary in stent restenosis, together with an overview of the current treatment modalities. The potential clinical utility of nanotechnology is also reviewed. The first human safety trial of systemic nanoparticle paclitaxel (nab-paclitaxel) for in stent restenosis (SNAPIST-I) is discussed. The results showed no significant adverse advents attributable to the nab-paclitaxel at 10 or 30 mg/m, although moderate neutropenia, sensory neuropathy and mild to moderate reversible alopecia occurred at higher doses. No major adverse cardiac events were recorded at 2 months, whilst at 6 months, 4 target lesions required revascularisation. The investigators concluded therefore that systemic nab-paclitaxel was well tolerated at a dose of <70 mg/m. To date however, no formal clinical evaluation has been reported as to the clinical utility of nab-paclitaxel, or any of the nano preparations discussed, for the suppression of coronary in stent restenosis.

AB - Coronary in stent restenosis remains a significant limitation to the long term efficacy of coronary artery stent placement. In this review the authors review the pathophysiology of coronary in stent restenosis, together with an overview of the current treatment modalities. The potential clinical utility of nanotechnology is also reviewed. The first human safety trial of systemic nanoparticle paclitaxel (nab-paclitaxel) for in stent restenosis (SNAPIST-I) is discussed. The results showed no significant adverse advents attributable to the nab-paclitaxel at 10 or 30 mg/m, although moderate neutropenia, sensory neuropathy and mild to moderate reversible alopecia occurred at higher doses. No major adverse cardiac events were recorded at 2 months, whilst at 6 months, 4 target lesions required revascularisation. The investigators concluded therefore that systemic nab-paclitaxel was well tolerated at a dose of <70 mg/m. To date however, no formal clinical evaluation has been reported as to the clinical utility of nab-paclitaxel, or any of the nano preparations discussed, for the suppression of coronary in stent restenosis.

U2 - 10.1186/2045-824X-3-8

DO - 10.1186/2045-824X-3-8

M3 - Article

VL - 3:8

JO - Vascular Cell

JF - Vascular Cell

SN - 2045-824X

ER -